Running Clinical Trials Across Borders: What Successful Global Studies Get Right

Drug development is increasingly global.

A single clinical trial may involve a sponsor in one country, a CRO in another, laboratories and technology providers across several regions, and investigative sites spread across multiple continents.

There are compelling reasons for this.

Multinational and multi-regional clinical trials can:

• Provide access to broader patient populations
• Support recruitment in uncommon diseases
• Improve population representation
• Generate evidence across different healthcare settings
• Support development programmes intended for multiple regulatory markets
• Potentially accelerate evidence generation

ICH E17 was specifically developed in recognition of the globalization of drug development and the importance of designing multi-regional clinical trials whose data can support regulatory submissions across regions. [1]

But adding countries does not automatically make a trial global.

A successful global trial requires something much more difficult:

One scientifically coherent study delivered reliably across multiple regulatory, healthcare, cultural and operational environments.

That is where global clinical development becomes both challenging and fascinating.

One Protocol Does Not Mean One Operational Environment

A multinational trial may use the same protocol everywhere.

But the environments in which that protocol is implemented can be very different.

Consider a study operating across the United States, Europe, India and Japan.

The protocol may be identical.

Yet differences may exist in:

Regulatory pathways

Ethics review

Standard of care

Clinical practice

Patient referral pathways

Contracting

Site infrastructure

Language

Data privacy requirements

Investigational product logistics

Laboratory practices

Cultural expectations

Recruitment behaviour

The challenge is therefore not to create a different clinical trial for every country.

It is to determine:

What must remain globally standardized—and what needs appropriate local adaptation?

That balance is at the heart of effective multinational trial management.

1. Global Strategy Should Begin Before Countries Are Selected

Country selection should not begin with:

“Where do we already have sites?”

It should begin with the scientific and operational needs of the study.

Important questions include:

• Where is the target patient population?
• How common is the indication?
• What is the local standard of care?
• Are required diagnostic tests routinely available?
• Are competing trials recruiting?
• Can the investigational product be imported and distributed?
• Are suitable investigators and sites available?
• What are realistic regulatory and ethics timelines?
• Can the country contribute meaningful enrollment within the recruitment window?
• Will data from the population support the development and regulatory strategy?

The countries with the largest populations are not automatically the best countries for a particular trial.

Country selection should be protocol-specific and evidence-informed.

2. Patient Population Matters Scientifically, Not Just Operationally

Global trials are not simply a strategy for finding more participants.

Population differences may influence treatment response.

ICH E17 emphasizes consideration of intrinsic and extrinsic factors when planning multi-regional clinical trials.

Intrinsic factors may include characteristics such as:

• Genetic factors
• Age
• Sex
• Body weight
• Organ function
• Disease characteristics

Extrinsic factors may include:

• Medical practice
• Diet
• Environmental factors
• Cultural influences
• Healthcare systems
• Concomitant therapies

These factors may potentially influence pharmacokinetics, pharmacodynamics, efficacy or safety.

A well-designed global programme therefore asks not only:

“Can this country recruit?”

but also:

“What does including this population contribute to the scientific interpretation of the study?”

3. Global Feasibility Needs Local Intelligence

Central feasibility data are valuable.

Epidemiology, historical trial performance, investigator databases and recruitment analytics can help identify potential countries and sites.

But numbers alone cannot tell the whole story.

Suppose epidemiological data suggest that a country has a substantial population with the target disease.

That does not necessarily mean those patients are accessible to research sites.

Patients may be:

• Concentrated in particular hospitals
• Managed primarily in community settings
• Referred only at advanced stages
• Treated through healthcare pathways incompatible with the protocol
• Already being recruited into competing trials

This is where local clinical operations expertise becomes essential.

The strongest feasibility strategy combines:

Global data + protocol understanding + local knowledge.

4. Regulatory Harmonization Helps—but Local Requirements Still Matter

Global clinical research has benefited substantially from international harmonization through ICH guidelines.

But harmonization does not mean that regulatory processes are identical everywhere.

Europe provides a useful example.

Under the EU Clinical Trials Regulation, the Clinical Trials Information System (CTIS) enables sponsors to submit a single online clinical trial application for authorization in up to 30 EU/EEA countries.

This is a major advance for multinational trial coordination.

However, authorization and oversight remain responsibilities of the relevant EU/EEA Member States, and country-specific aspects still need to be addressed appropriately.

Outside Europe, sponsors may encounter different:

• Regulatory submission pathways
• Ethics requirements
• Import/export processes
• Safety-reporting requirements
• Data requirements
• Document requirements
• Timelines

Global regulatory strategy therefore requires both harmonized thinking and country-level execution.

5. Ethics Is Global—but Consent Must Work Locally

The ethical principles underpinning clinical research should not change according to geography.

Participant rights, safety, well-being and voluntary informed consent remain fundamental.

But how information is communicated may need local adaptation.

Participant-facing documents may require:

• Translation
• Cultural adaptation
• Appropriate readability
• Local contact information
• Country-specific compensation information
• Local data-protection wording
• Locally required consent elements

A technically accurate translation is not necessarily an understandable translation.

For informed consent to be meaningful, participants need information they can genuinely comprehend.

Localization therefore should not be treated as a final administrative step.

It is part of participant protection.

6. Site Selection Becomes Even More Important Globally

In multinational studies, weak site selection can become extremely expensive.

Opening an underperforming domestic site is problematic.

Opening an underperforming site in another country may also involve:

• Regulatory submissions
• Translation
• Contracts
• Budgets
• Site initiation
• Investigational product shipment
• Laboratory setup
• Technology access
• CRA resources
• Ongoing oversight

All before a single participant is enrolled.

Global site selection therefore needs to assess more than investigator interest.

A site should be evaluated for:

Patient access

Research infrastructure

Investigator experience

CRC capacity

Protocol feasibility

Competing studies

Start-up capability

Recruitment potential

Quality history

Operational responsiveness

The objective should never simply be to create a long global site list.

The objective is to create a productive site network.

7. Start-Up Timelines Can Determine the Value of a Country

Imagine two countries.

Country A could recruit 30 participants per year but requires a long start-up period.

Country B could recruit 20 participants per year but can begin substantially earlier.

Which is better?

The answer depends on the study timeline.

If recruitment closes before Country A has enough time to contribute meaningfully, its theoretical annual recruitment potential becomes less relevant.

Global feasibility therefore needs to consider:

Recruitment potential × time available after activation

not recruitment potential alone.

This is one reason why regulatory, ethics, contracting and site-start-up timelines need to be incorporated into country strategy from the beginning.

8. Contracts and Budgets Are Clinical Trial Timelines

Contracts are sometimes treated as an administrative workstream running in parallel with “real” clinical operations.

In practice, a site cannot recruit until critical contractual and budget requirements are resolved.

Global studies may involve:

• Clinical Trial Agreements
• Site budgets
• Institutional overheads
• Payment schedules
• Indemnification
• Insurance
• Data-related clauses
• Publication terms
• Local legal requirements

Negotiation practices may differ considerably between countries and institutions.

Contracting should therefore be incorporated into study planning rather than viewed as a final administrative hurdle.

A site that is scientifically ready but contractually blocked is still not an active site.

9. Global Studies Need Strong Local CRAs and CRCs

Technology enables centralized oversight across continents.

But clinical trials are still delivered locally.

CRAs understand:

• Site performance
• Investigator engagement
• Protocol implementation
• Documentation
• Participant-safety processes
• Operational risks

CRCs frequently coordinate the practical day-to-day delivery of the trial at site level.

In multinational studies, local professionals can also understand nuances that may not be visible to a central project team:

• Language
• Institutional culture
• Clinical workflow
• Local holidays
• Patient behaviour
• Referral patterns
• Communication expectations

Global clinical operations therefore works best when central governance is supported by strong local execution.

10. Language Is an Operational Risk

English may be the global working language for many development programmes.

But that does not mean every trial activity can or should occur only in English.

Depending on the country and applicable requirements, local-language materials may be needed for:

• Participants
• Ethics submissions
• Regulatory submissions
• Site communication
• Safety information
• Contracts
• Training materials

Translation introduces its own risks.

An incorrectly translated eligibility criterion, dosing instruction or safety statement could have significant consequences.

Global trials therefore need controlled processes for:

translation → review → approval → version control → implementation.

Language management is not merely a publishing function.

It is part of clinical trial quality.

11. Investigational Product Supply Is a Global Supply-Chain Challenge

The investigational product must reach the right site, in the right condition, at the right time.

Across countries, this can involve:

• Manufacturing
• Packaging
• Labelling
• Import licences
• Customs
• Depots
• Temperature-controlled shipment
• Site storage
• Accountability
• Resupply
• Returns and destruction

Country-specific labelling or import requirements can affect timelines.

A delay in investigational product supply can create an unusual situation:

The site is activated.

The patient is available.

The investigator is ready.

But enrollment cannot proceed.

Global study planning therefore requires early integration of clinical operations with supply-chain strategy.

12. Safety Must Travel Faster Than Geography

A serious safety event occurring at a site in one country may have implications for participants everywhere.

Global pharmacovigilance therefore requires reliable pathways connecting:

Site → Local clinical operations → Sponsor/CRO → Safety database → Medical assessment → Regulatory reporting → Investigators/authorities as required

This becomes increasingly complex when local reporting obligations coexist with global sponsor processes.

Safety teams need to understand:

• Global standards
• Country-specific requirements
• Reporting timelines
• Reference safety information
• Local ethics requirements
• Regulatory interfaces

The safety system must operate as one connected global process, even when reporting obligations differ locally.

13. Data Must Mean the Same Thing Everywhere

Imagine 20 countries collecting the same endpoint but interpreting the assessment differently.

The database may appear complete.

Scientifically, however, the study could be compromised.

Global trials therefore require standardization of:

• Endpoint definitions
• Data collection
• Clinical assessments
• Laboratory methods
• Imaging
• Coding
• Training
• Data-entry expectations

Central laboratories, blinded endpoint committees, standardized imaging review and structured training may help reduce variability where appropriate.

But standardization must be purposeful.

The objective is not identical bureaucracy in every country.

It is comparable and interpretable evidence.

14. Technology Creates Connectivity—and Dependency

Modern global trials depend heavily on technology.

Sites across countries may interact with:

EDC

CTMS

eTMF

RTSM/IRT

eCOA/ePRO

Safety databases

Central laboratory portals

Imaging systems

Technology enables near-real-time global coordination.

But it also creates dependency.

Teams must consider:

• System validation
• User access
• Training
• Data privacy
• Cybersecurity
• Internet reliability
• Integration
• Technical support across time zones

A system that works perfectly at headquarters but is difficult for sites to use is not a successful global system.

Technology must work where the trial is actually conducted.

15. Vendor Oversight Becomes More Complex Across Borders

A global study may involve numerous providers:

• Global CRO
• Local CROs
• Central laboratory
• Imaging vendor
• EDC provider
• Safety database provider
• Translation vendor
• Logistics provider
• Home-health provider
• Patient recruitment provider

This creates a network of delegated activities.

But delegation does not remove sponsor responsibility for appropriate oversight.

ICH E6(R3) reinforces sponsor responsibility for selecting qualified investigators and service providers and for maintaining appropriate oversight of transferred activities.

Effective global vendor management therefore requires:

Clear responsibilities

Governance

Communication

Performance metrics

Risk management

Escalation pathways

Quality oversight

A global trial should not become a collection of disconnected vendors.

It needs to operate as one coordinated programme.

16. Centralization Does Not Mean Micromanagement

Global studies require central governance.

But central governance should not mean every local decision needs headquarters approval.

That creates bottlenecks.

A mature operating model defines:

What is globally standardized?

For example:

• Protocol
• Core study processes
• Data standards
• Safety governance
• Quality framework
• Reporting expectations

What can be locally adapted?

For example:

• Site communication
• Recruitment tactics
• Operational scheduling
• Certain country-specific documentation
• Locally required processes

What requires escalation?

For example:

• Participant-safety issues
• Significant protocol deviations
• Serious breaches
• Major recruitment risks
• Regulatory issues
• Critical quality findings

The objective is control without unnecessary complexity.

17. Communication Is Infrastructure

Many global study problems are not caused by lack of expertise.

They are caused by fragmented communication.

Consider:

A site identifies a recruitment barrier.

↓

The CRA knows.

↓

The local clinical operations lead knows.

↓

But the global study team does not learn about it for six weeks.

By then, the same issue may be affecting several countries.

Global trial governance therefore needs clear communication architecture:

Who reports what?

To whom?

How quickly?

Where is the decision documented?

Who owns the action?

Meetings alone do not create governance.

Governance requires decision pathways and accountability.

18. A Global Trial Should Still Feel Like One Trial

Perhaps the clearest indicator of successful multinational operations is consistency.

A participant in Country A and a participant in Country B may interact with different languages, healthcare systems and investigators.

But the underlying trial should still maintain the same:

• Scientific question
• Ethical standards
• Critical procedures
• Endpoint definitions
• Quality expectations
• Safety principles
• Data integrity requirements

That is the challenge of global clinical research:

Local execution without scientific fragmentation.

Global Trials and Regulatory Acceptability

The reason this matters extends beyond operations.

Global development programmes ultimately need evidence that regulators can interpret.

ICH E17 was developed specifically to improve the planning and design of multi-regional clinical trials and increase their acceptability in global regulatory submissions.

Likewise, FDA requires foreign clinical studies submitted in support of U.S. applications under applicable circumstances to meet defined standards, including Good Clinical Practice requirements involving independent ethics review and informed consent.

A study being conducted outside a sponsor's home country does not make the evidence less rigorous.

The expectation remains:

qualified investigators + ethical research + reliable data + appropriate oversight.

The Formula for Successful Global Trial Delivery

Successful global studies bring several elements together:

Strong scientific design

•  

Intelligent country strategy

•  

Evidence-based feasibility

•  

The right sites

•  

Local regulatory expertise

•  

Experienced CRAs and CRCs

•  

Integrated safety and data systems

•  

Strong vendor governance

•  

Clear communication

•  

Central oversight

=

A globally coordinated clinical trial capable of generating reliable evidence

Remove one of these elements and the programme becomes more vulnerable.

The Agile Clinical Trendz Perspective

At Agile Clinical Trendz, we believe global clinical trial delivery requires more than coordinating sites across different countries.

It requires an operating model that connects:

global strategy with local expertise.

That means understanding the protocol centrally while understanding the healthcare environment locally.

It means maintaining consistent quality expectations while respecting country-specific regulatory and operational requirements.

It means integrating clinical operations, site management, CRAs, CRCs, regulatory activities, pharmacovigilance, biometrics, data management, medical writing, quality and technology within one coherent study framework.

And it means recognizing that local partners are not simply execution resources.

They are an important source of operational intelligence.

The goal of a global trial should therefore never simply be:

“Run the same protocol in many countries.”

It should be:

“Generate one reliable body of evidence through coordinated execution across diverse healthcare environments.”

Because successful globalization in clinical research is not defined by how many countries appear on the study map.

It is defined by whether every country contributes effectively to the same scientific objective.

References

1. International Council for Harmonisation. ICH E17: General Principles for Planning and Design of Multi-Regional Clinical Trials. 2017.
2. International Council for Harmonisation. ICH E6(R3): Guideline for Good Clinical Practice. Final Guideline. 2025.
3. International Council for Harmonisation. ICH E8(R1): General Considerations for Clinical Studies. 2021.
4. European Parliament and Council. Regulation (EU) No 536/2014 on Clinical Trials on Medicinal Products for Human Use.
5. European Medicines Agency. Clinical Trials Regulation. EMA.
6. European Medicines Agency. Clinical Trials Information System (CTIS). EMA.
7. U.S. Food and Drug Administration. Acceptance of Foreign Clinical Studies Not Conducted Under an IND. 21 CFR 312.120 and related FDA guidance.
8. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. 2024 revision.